Immix Biopharma, Inc. 4

Jason Hsu received 6,250 RSUs and a stock option for 12,500 shares of Immix Biopharma, Inc. common stock as equity compensation awards.

On May 22, 2026, Jason Hsu of Immix Biopharma, Inc. received equity compensation consisting of 6,250 restricted stock units (RSUs) of common stock and a stock option to purchase 12,500 shares of common stock at an exercise price of $8.78 per share, both granted under the issuer’s 2021 Equity Incentive Plan. The RSUs will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 annual stockholders’ meeting, contingent on continued service, while the option vests in substantially equal monthly installments over 12 months (or fully at the 2027 annual meeting if that occurs earlier), also subject to continued board service. Following these awards, Hsu holds 899,250 shares of common stock directly, plus indirect interests in 3,915,913 and 50,000 shares held through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, respectively, for which he disclaims beneficial ownership beyond his pecuniary interest, as well as 12,500 option shares underlying the new grant. Based on the $8.78 option exercise price as a proxy for the stock price, the RSU grant is valued at approximately $54,875 and the new option grant has a notional exposure of about $109,750, indicating a routine but meaningful refresh of his equity-based compensation rather than an open-market purchase or sale.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

4

Source Type

sec

Accession

0001493152-26-026422

Alert Tier

5